Esophageal candidiasis as a complication of inhaled corticosteroids

Annals of Allergy, Asthma and Immunology

Volumn 79, Issue 4, 1997, Pages 333-338

  Simon, Michael R ^a,b,c   Houser, William L ^a,b   Smith, Kurtis A ^a,b   Long, P Michael ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 111F V A Medical Ctr   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; IPRATROPIUM BROMIDE; PIRBUTEROL; RANITIDINE; TRIAMCINOLONE ACETONIDE;

AGED; ARTICLE; ASTHMA; CANDIDIASIS; CASE REPORT; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; ESOPHAGITIS; ESOPHAGOSCOPY; FEMALE; GASTRITIS; GASTROSCOPY; HUMAN; IMMUNE DEFICIENCY; INHALATIONAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030734567     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63024-4     Document Type: Article

References (44)

1. Cockcroft DW, Murdock KY. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. J Allergy Clin Immunol 1987;79: 734-40.
2. Barnes PJ. A new approach to the treatment of asthma. N Engl J Med 1989;321:1517-22.
3. National Asthma Education Program Expert Panel Report Executive Summary: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health, Bethesda, MD. Publication No. 91-3042A, June 1991.
4. Konig P. Inhaled corticosteroids -their present and future role in the management of asthma. J Allergy Clin Immunol 1988;82:297-305.
5. Toogood JH, Baskerville J, Jenning B, et al. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol 1989;84:688-700.
6. Kennedy MCS, Haslock MR, Thursby-Pelham DC. Aerosol therapy for asthma: a 10-year follow-up of treatment with beclomethasone dipropionate in 100 asthmatic patients. Pharmatherapeutica 1981;2:648-57.
7. Spector SL, Wangaard C, Bardana EJ. The use of cultures and immunologic procedures to predict oropharyngeal candidiasis in patients on steroid aerosols. Allergy 1982;12:269-78.
8. Williams AJ, Baghat MS, Stableforth DE, et al. Dysphonia caused by inhaled steroids: recognition of a characteristic laryngeal abnormality. Thorax 1983;38:813-21.
9. Kesten S, Hyland RH, Pruzanski WR, Kortan PP. Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy. Drug Intelligence Clin Pharm 1988;22:568-9.
10. Sievert W, Holmes P, King RWF. Oesophageal candidosis in patients on high dose inhaled steroids. Lancet 1992;339:1551-2.
11. Oppenheim JJ, Schecter B. Lymphocyte transformation. In: Rose NR, Friedman H, eds. Manual of clinical immunology. Washington DC: American Society for Microbiology 1976: 81-94.
12. Lehrer RI, Cline MJ. Interaction of Candida albicans with human leukocytes and serum. J Bacteriol 1969;98: 996-1004.
13. Terr AI. Allergic diseases. In: Stites DP, Stobo JD, Fudenberg HH, Wells JV, eds. Basic and clinical immunology. Fifth Edition, Los Altos, CA: Lange Medical Publications 1980: 500-19.
14. Anderson LI, Frederiksen H-J, Apple-yard M. Prevalence of esophageal Candida colonization in a Danish populalion, with special reference to esophageal symptoms, benign esophageal disorders, and pulmonary disease. J Infec Dis 1992;165:389-92.
15. McDonald GB. Esophageal diseases caused by infection, systemic illness, medications, and trauma. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal disease, pathophysiology/ diagnosis/management Philadelphia: WB Saunders Company, 1993: 427-55.
16. Slavin RG, Tennenbaum JI, Becker RJ, et al. Cell transfer of delayed hypersensitivity to ragweed from atopic subjects treated with emulsified ragweed extracts. J Allergy 1963;34: 368-73.
17. Kaaman T. The clinical significance of cutaneous reactions Io trichophytin in dermatophytosis. Acta Dermatovenereol 1978;58:139-43.
18. Rajka G, Barlinn C. On the significance of the trichophytin reactivity in atopic dermatitis. Acta Dermatovenereol 1979;59:45-7.
19. Tarlo SM, Day JH, Mann P, Day MP. Immediate hypersensitivity to tuberculin: in vivo and in vitro studies. Chest 1977;71:33-7.
20. Rudzki E, Moskalewska K, Maciejowska E, Blaszczyk M. Fruhallergie auf Streptokokken und Staphy-lokokken bei Menschen und experimentell infizierten Kaninchen. Arch Klin Exp Dermatol 1964;220: 535-46.
21. Sipos K. Analyse der intracutanen Reaktionen von Pyokokkenantigenen. Arch Klin Exp Dermatol 1965;222: 430-51.
22. Simon MR. Leukocyte function in human allergic disease. In: Phillips SM, Escobar MR, eds. The reticuloendothelial systems, vol 9. Plenum Publishing Corp. 1986:125-71.
23. Marone G, Thomas LL, Lichtenstein LM. The role of agonists that activate adenylate cyclase in the control of cAMP metabolism and enzyme release by human polymorphonuclear leukocytes. J Immunol 1980;125:2277-83.
24. Wang SR, Zweiman B. Inhibitory effects of corticosteroids and histamine on human lymphocytes. J Allergy Clin Immunol 1981;67:39-44.
25. Herlin T, Kragballe K. Impaired monocyte cyclic AMP responses and monocyte cytotoxicity in atopic dermatitis. Allergy 1980;35:647-55.
26. Ogden BE, Kreuger GG, Hill HR. Lymphocyte suppressor activity in atopic eczema. Clin Exp Immunol 1979;35:269-75.
27. Krause DS, Deutsch C. Cyclic AMP directly inhibits IL-2 receptor expression in human T cells: expression of both p55 and p75 subunits is affected. J Immunol 1991;146:2285-94.
28. Novak TJ, Rothenberg EV. cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells. Proc Natl Acad Sci USA 1990;87:4353-7.
29. Wacholtz MC, Minakuchi R, Lipski PE. Characterization of the 3′,5′-cyclic adenosine monophosphatemediated regulation of IL 2 production by T cells and Jurkat cells. Cell Immunol 1991;135:285-98.
30. Gallin JI, Sandler JA, Clyman RI, et al. Agents that increase cyclic AMP inhibit accumulation of cGMP and depress human monocyte locomotion. J Immunol 1978;120:492-6.
31. Rocklin RE, Breard J, Gupta S, et al. Characterization of the human blood lymphocytes that produce a histamine-induced suppressor factor (HSF). Cell Immunol 1980;51:226-37.
32. Meretey K, Room G, Maini RN. Effects of histamine on the mitogenic response of human lymphocytes and its modification by cimetidine and levamisole. Agents Actions 1981;11: 84-8.
33. Damle NK, Gupta S. Autologous mixed lymphocyte reaction in man. II. Histamine-induced suppression of the autologous mixed lymphocyte reaction by T-cell subsets defined with monoclonal antibodies. J Clin Immunol 1981;1:241-9.
34. Rocklin RE, Melmon KL. Production and assay of a histamine-induced suppressor factor (HSF) by human lymphocytes. Clin Res 1978;26:520A.
35. Gifford RR, Sr, Hatfield SM, Schmidtke JR. Cimetidine-induced augmentation of human lymphocyte blastogenesis by mitogen, bacterial antigen, and alloantigen. Transplantation 1980;29:143-8.
36. Palacios R, Alarcon-Segovia D. Cimetidine abrogates suppressor T cell function in vitro. Immunol Lett 1981; 3:33-7.
37. Thomas Y, Huchet R, Granjon D. Histamine-induced suppressor cells of lymphocyte mitogenic response. Cell Immunol 1981;59:268-75.
38. Simon MR, Salberg DJ, Crane SA. In vivo cimetidine augmentation of phytohemagglutinin induced human lymphocyte thymidine uptake. Transplantation 1981;31:400-2.
39. 2 histamine receptors. Immunol 1980;41:107-14.
40. Beer DJ, Rosenwasser LJ, Dinarello CA, Rocklin RE. Cellular interactions in the generation and expression of histamine-induced suppressor activity. Cell Immunol 1982;69:101-12.
41. Breuillard F, Szapiro E. Cimetidine in a acquired tolerance to dinitrochlorobenzene [Letter]. Lancet 1978;1:726.
42. Daman LA, Rosenberg EW, Drake L. Treatment of alopecia areata with dinitrochlorobenzene. Arch Dermatol 1978;114:1036-8.
43. Jorizzo JL, Sams WM, Jr, Jegasothy BV, Olansky AJ. Cimetidine as an immunomodulator: chronic mucocutaneous candidiasis as a model. Ann Intern Med 1980;92:192-5.
44. Simon MR. Cimetidine and immunologic response [Letter]. Ann Intern Med 1980;93:152.